A blood-based mRNA signature distinguishes people with Long COVID from recovered individuals
Downregulation of these inhibitory receptors similarly indicates a sustained pro-inflammatory state in Long COVID PBMCs. <i>LILRB1</i> and <i>LILRB2</i> should be validated as prospective biomarkers of Long COVID in larger cohorts, over time and against clinically overlapping conditions.
Authors
- Paul Fisher (ORCID: https://orcid.org/0000-0002-4066-1810)
- Esmaeil Ebrahimie (ORCID: https://orcid.org/0000-0002-4431-2861)
- Manijeh Mohammadi‐Dehcheshmeh (ORCID: https://orcid.org/0000-0002-8019-4081)
- Claire Y. Allan (ORCID: https://orcid.org/0000-0002-4113-3163)
- Sarah J. Annesley (ORCID: https://orcid.org/0000-0002-7604-3985)
- Oana Sanislav (ORCID: https://orcid.org/0000-0002-9335-3344)
- Daniel Missailidis (ORCID: https://orcid.org/0000-0001-6755-2959)
- Stéphanie Gras (ORCID: https://orcid.org/0000-0001-7416-038X)
Institutions
- La Trobe University (AU)
- Monash University (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-03
- DOI
- https://doi.org/10.3389/fimmu.2024.1450853
- Citations
- 9
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 3.32
Funders
- La Trobe University
- National Health and Medical Research Council